MedPath

A clinical study to evaluate safety andEffectiveness of the Elure advanced skin whitening products (Advanced whitening lotion andAdvanced whitening night cream) in imparting skin fairness on healthy human volunteers.

Phase 2
Completed
Registration Number
CTRI/2012/01/002363
Lead Sponsor
Syneron P Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
40
Inclusion Criteria

Female subjects in generally good health.

Subject can read and comprehend with the English informed consent form.

Subjects of skin types III, IV, and V.

Subjects age group 18 - 60 years

Subjects willing to give a written informed consent and come for a regular follow up.

Subject willing to abide by and comply with the study protocol

Subject has not participated in a similar investigation in the past four weeks.

Subjects having post inflammatory hyperpigmentation, freckles, pigmented demarcation lines, and uneven tone skin will also be included.

The subject will be enrolled after the sensitivity test is negative for all the sites

Exclusion Criteria

A known history or present condition of allergic response to any cosmetic products.

Subject having skin diseases (e.g. moderate to severe acne vulgaris face or nodulocystic acne, psoriasis, active atopic dermatitis, melasma, lichen planus pigmentosus/ Achy dermatosis, pigmented contact dermatitis or other cutaneous manifestations), which will interfere with the test readings.

Subjects on oral medications (e.g. steroids, anti-oxidant) which will compromise the study.

Systemic treatment which may modify the cutaneous state on the day of inclusion or in the previous 30 days, including retinoid therapy.

Subjects not willing to discontinue other fairness/whitening/ brightening creams including vitamin A derivatives.

Subjects who are pregnant, lactating or nursing.

Hypersensitivity to any component of the tested products.

History of intense sun exposure.

Chronic illness which may influence the cutaneous state.

Subject participating in any other cosmetic or therapeutic trial.

Any underlying uncontrolled medical illness including diabetes mellitus, hypertension, liver disease or history of alcoholism, HIV, hepatitis, or any other serious medical illness.

Subject having any sensitive reaction to the investigational product- Skin Sensitivity test.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.Improvement in whitening property of skin in comparison to baseline. <br/ ><br>2.Improvement in melanin values in Mexameter readings in comparison to baseline readings. <br/ ><br>3.Improvement in L value in Chromameter readings in comparison to baseline readings. <br/ ><br>Timepoint: Day 1, Day 15, Day 28, Day 56, Day 84
Secondary Outcome Measures
NameTimeMethod
ilTimepoint: Nil
© Copyright 2025. All Rights Reserved by MedPath